Press Release on Financial Results for the year ended 31.03.2026

Guidance RaisedBusiness Updates View source PDF

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.5%1-day move

₹381.50

prior close

₹385.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.1-1.3-2.1-3.2-1.5-0.7-2.8-6.0-5.5-7.2-1.3-1.1+2.8—

Up moveDown movePending

AI summary

SMS Pharmaceuticals reported strong FY26 results with PAT growing 48% YoY to ₹102 crore, driven by backward integration and improved product mix. Revenue grew 13% to ₹887 crore, while EBITDA margin expanded 155 bps to 19%. The company completed 12 DMF and CEP filings in FY26 and has a ₹280 crore capex programme on track for FY27 completion. Key growth drivers include anti-inflammatory APIs (20% growth) and ARV APIs (55% growth), while anti-diabetic segment was scaled back by 30%. The board recommended a dividend of ₹0.40 per share.

Likely market impact

The company has raised its FY27 outlook to over 15% revenue growth with EBITDA margins around 20%, indicating stronger-than-expected profitability ahead. This positive guidance and margin expansion trajectory could be viewed favorably by investors.